Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

allergan pharmaceuticals ireland - toxina botulinica de tip a - pulb. pt. sol. inj. - 100unitati - miorelaxante periferice alte miorelaxante cu actiune periferica

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

allergan pharmaceuticals ireland - toxina botulinica de tip a - pulb. pt. sol. inj. - 200unitati - miorelaxante periferice alte miorelaxante cu actiune periferica

Evropská unie - rumunština - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresoare - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Evropská unie - rumunština - EMA (European Medicines Agency)

h. lundbeck a/s - nalmefen formă de clorhidrat dihidrat - tulburări legate de alcool - medicamente utilizate în dependența de alcool - selincro este indicat pentru reducerea consumului de alcool la pacienţii adulţi cu dependenţă de alcool care au un nivel ridicat de risc de băut (vezi sectiunea 5. 1), fără simptome fizice de retragere și care nu necesită detoxificare imediată. selincro ar trebui să fie prescris numai în legătură continuă cu suport psiho-social axat pe aderentei la tratament și reducerea consumului de alcool. selincro ar trebui să fie inițiată numai la pacienții care continuă să aibă o mare de băut-nivel de risc de două săptămâni după evaluarea inițială.

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ferring gmbh - germania - combinatii - pulb. pt. sol. orala - laxative laxative de contact

Rumunsko - rumunština - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

delpharm tours - franta - combinatii (tropicamidum+phenylephrinum+lidocainum) - sol. inj. - 0,2mg/ml+3,1mg/ml+10mg/ml - midriatice si cicloplegice anticholinergice

Moldavsko - rumunština - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

octapharma pharmazeutika produktionsges. m.b.h - factorul viii de coagulare uman - pulbere şi solvent pentru soluţie injectabilă - 250 ui

Moldavsko - rumunština - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

octapharma pharmazeutika produktionsges. m.b.h - factorul viii de coagulare uman - pulbere şi solvent pentru soluţie injectabilă - 500 ui

Moldavsko - rumunština - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

octapharma pharmazeutika produktionsges. m.b.h - factorul viii de coagulare uman - pulbere şi solvent pentru soluţie injectabilă - 1000 ui

Evropská unie - rumunština - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriazis - imunosupresoare - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.